CASI Pharmaceuticals (CASI) has released an update.
CASI Pharmaceuticals has announced the appointment of Daniel Lang, MD as their new Chief Financial Officer and Senior Vice President, starting July 8, 2024. With over three decades of experience in the medical and investment fields, Dr. Lang is expected to advance the company’s strategic initiatives, particularly focusing on their anti-CD38 program and the promising CID-103 for autoimmune diseases. CASI Pharmaceuticals specializes in developing and commercializing innovative therapeutics, aiming to be a leader in the Greater China market.
For further insights into CASI stock, check out TipRanks’ Stock Analysis page.
